Next-Generation Targeted Therapy in B-Cell Malignancies: CaDAnCe-101 (BGB-16673)

Dr Shadman frames the clinical need for treatment mechanisms beyond conventional BTK inhibition in patients with relapsed or refractory B-cell malignancies.

Dr Shadman explains how BTK degradation differs mechanistically from BTK inhibition.

Dr Shadman contextualizes the efficacy of the BTK degrader catadegbrutinib in relapsed or refractory Waldenström macroglobulinemia, where it produced an overall response rate of 83.7%, a major response rate of 76.7%, and a very good partial response rate of 30.2% at a median follow-up of 16.6 months.

Dr Shadman outlines the key open questions and later-phase data to watch for both programs.